SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: reaper247, BottomWatcher , Rat Fink, fuzzymcilwoods, ninersax, BLight1911
Search This Board: 
Last Post: 9/23/2017 9:05:38 PM - Followers: 164 - Board type: Free - Posts Today: 0

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman
 
 


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\



 





 


https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12149068

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
AEPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP News: Statement of Changes in Beneficial Ownership (4) 09/14/2017 12:59:14 PM
AEPP News: Information Statement - All Other (definitive) (def 14c) 09/06/2017 10:55:34 AM
AEPP News: Securities Registration Statement (s-1) 08/29/2017 06:10:32 AM
AEPP News: Proxy Statement - Other Information (preliminary) (pre 14c) 08/22/2017 06:06:03 AM
AEPP News: Quarterly Report (10-q) 08/18/2017 05:09:11 PM
PostSubject
#11627  Sticky Note LOL, DayDreeming, reaper247 09/18/17 10:38:55 PM
#11604  Sticky Note Massive dilution is just around the corner......... DayDreeming 09/18/17 03:39:45 PM
#10796  Sticky Note Investors here are protected from dilution for a dabullishbear 08/29/17 02:02:06 PM
#8084  Sticky Note AEPP/Oncolix summary. reaper247 07/20/17 06:32:22 PM
#11759   A lot of potential for AEPP moving forward. reaper247 09/23/17 12:06:17 AM
#11758   Hope u have a good one to ....thanks Pinky4 09/22/17 07:32:22 PM
#11757   You're welcome. Hope everyone has a great weekend. Bored Lawyer 09/22/17 05:04:06 PM
#11756   nice article, thx for sharing Eltp 09/22/17 04:20:36 PM
#11755   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038960/ Bored Lawyer 09/22/17 03:06:05 PM
#11753   I've never claimed that Prolanta works (or does Bored Lawyer 09/22/17 03:00:46 PM
#11751   Having patents doesn't mean the treatment works. There's ninersax 09/22/17 02:32:27 PM
#11749   Degree or no degree, who cares. CatfishHunter 09/22/17 02:07:04 PM
#11748   At the University of Phoenix with Shaq? laraz5 09/22/17 01:52:38 PM
#11747   OMG you know what's even crazier that that? dabullishbear 09/22/17 01:33:24 PM
#11746   Heck, I'll even save you the time on Bored Lawyer 09/22/17 01:30:34 PM
#11745   Transparent lies and blatant mis-information on the website DayDreeming 09/22/17 01:27:57 PM
#11744   Please spend 10 minutes searching the patent database, Bored Lawyer 09/22/17 01:26:36 PM
#11741   Futhermore, he is no longer a "full-professor at DayDreeming 09/22/17 01:24:42 PM
#11739   Haha nice try. Everything is 100% transparent here. dabullishbear 09/22/17 01:19:19 PM
#11738   Lots of buying volume today. Shows a great ninersax 09/22/17 01:03:50 PM
#11737   Patent clarification - BLight1911 09/22/17 12:17:39 PM
#11736   What! I Can't believe I over looked that, laraz5 09/22/17 12:17:09 PM
#11735   Patent clarification. There has been a lot of DayDreeming 09/22/17 11:48:49 AM
#11734   It's almost time. steadyhand 09/22/17 10:47:25 AM
#11732   Not a scam buy buy buy dabullishbear 09/22/17 09:57:59 AM
#11730   agree, some big bids under .05.....200k at .047 microcaptrdr24 09/22/17 09:36:51 AM
#11729   Yes, I believe we are! Bored Lawyer 09/22/17 09:34:56 AM
#11728   Today might be a day people start loading Sungod95 09/22/17 09:12:19 AM
#11727   Hmm idk. I like the way that looks though. dabullishbear 09/21/17 11:42:36 PM
#11726   Here's a link to the tweet and you BLight1911 09/21/17 11:41:23 PM
#11725   Who knows but I enjoy his list especially dabullishbear 09/21/17 11:37:24 PM
#11724   There's a new logo I saw on the BLight1911 09/21/17 11:35:01 PM
#11723   I asked Redman if they were changing their dabullishbear 09/21/17 11:33:36 PM
#11722   Thanks Bored Lawyer. reaper247 09/21/17 10:23:20 PM
#11721   Giddyup Oncolix!! Yeehawww!! CatfishHunter 09/21/17 06:59:31 PM
#11720   Looks like they are changing their logo too. BLight1911 09/21/17 06:53:55 PM
#11719   October is going to be a big month. dabullishbear 09/21/17 05:16:22 PM
#11718   Small Cap Voice article out. BLight1911 09/21/17 04:31:29 PM
#11717   Big money trades going on here...lol ninersax 09/21/17 04:01:43 PM
#11716   Oncolix, Inc. to Present at The MicroCap Conference molee 09/21/17 12:53:36 PM
#11715   Oncolix will also present at the Microcap Conference microcaptrdr24 09/21/17 11:50:06 AM
#11714   Nice post reaper. My guess is the Bored Lawyer 09/21/17 11:18:14 AM
#11713   September 26th should be a good day for Oncolix: Bored Lawyer 09/21/17 11:17:21 AM
#11710   Agreed, in Redman we trust. BLight1911 09/21/17 09:05:39 AM
#11709   Now we know why Redman thanked AEPP investors DayDreeming 09/21/17 08:55:12 AM
#11708   Thanks for the DD. BLight1911 09/21/17 08:42:53 AM
#11707   Why would Redman sell shares at this stage DayDreeming 09/21/17 08:15:09 AM
#11706   Looks like the AEPP follies will be ending soon. reaper247 09/21/17 02:14:08 AM
#11701   M.D. ANDERSON'S PRE-CLINCAL TRIAL "ONCOLIX" PROLANTA (G129R) http://nebula.wsim Rat Fink 09/20/17 09:46:54 PM
#11700   Oncolix has never claimed that Prolanta "kills cancer". BLight1911 09/20/17 09:25:21 PM
#11699   What do they use to kill it? Only Airstock 09/20/17 09:14:41 PM
#11696   You can kill cancer with bleach? What does BLight1911 09/20/17 08:49:39 PM
#11695   "His kids are made up it's are also? BLight1911 09/20/17 08:46:12 PM
#11693   Well luckily for me their shares are restricted dabullishbear 09/20/17 08:38:26 PM
PostSubject